CL2022003348A1 - Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios - Google Patents

Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios

Info

Publication number
CL2022003348A1
CL2022003348A1 CL2022003348A CL2022003348A CL2022003348A1 CL 2022003348 A1 CL2022003348 A1 CL 2022003348A1 CL 2022003348 A CL2022003348 A CL 2022003348A CL 2022003348 A CL2022003348 A CL 2022003348A CL 2022003348 A1 CL2022003348 A1 CL 2022003348A1
Authority
CL
Chile
Prior art keywords
compositions
methods
treatment
acute respiratory
respiratory distress
Prior art date
Application number
CL2022003348A
Other languages
English (en)
Inventor
L Chang Richard
Y Chang Ben
Original Assignee
Phor Med Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phor Med Inc filed Critical Phor Med Inc
Publication of CL2022003348A1 publication Critical patent/CL2022003348A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSICIONES Y MÉTODOS PARA TRATAR EL SÍNDROME DE DIFICULTAD RESPIRATORIA AGUDA.
CL2022003348A 2020-05-28 2022-11-28 Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios CL2022003348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063031551P 2020-05-28 2020-05-28

Publications (1)

Publication Number Publication Date
CL2022003348A1 true CL2022003348A1 (es) 2023-12-01

Family

ID=78722786

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003348A CL2022003348A1 (es) 2020-05-28 2022-11-28 Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios

Country Status (12)

Country Link
US (3) US20230248684A1 (es)
EP (1) EP4304570A4 (es)
JP (1) JP2023528804A (es)
KR (1) KR20230058014A (es)
CN (1) CN117015375A (es)
AU (1) AU2021281257A1 (es)
BR (1) BR112022024226A2 (es)
CA (1) CA3180577A1 (es)
CL (1) CL2022003348A1 (es)
IL (1) IL298593A (es)
MX (1) MX2022014958A (es)
WO (1) WO2021243007A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
US12521475B2 (en) * 2020-04-08 2026-01-13 Arizona Board Of Regents On Behalf Of Arizona State University Method, device, and product for treating a body fluid of a patient with an inflammatory cytokine storm by binding an antibody to a cytokine antigen in the body fluid to form an antigen-antibody complex that is removed from the body fluid to reduce the amount of the cytokines in the body fluid
EP4135727A4 (en) * 2020-04-16 2024-05-22 University of Pittsburgh - of the Commonwealth System of Higher Education MATRIX-BOUND VESICLES (MBV) FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist
CN115252760B (zh) * 2022-03-30 2024-05-31 厦门大学 一种广谱抗冠状病毒的制剂及其制备方法
WO2025029797A1 (en) * 2023-08-01 2025-02-06 Incelldx, Inc. Methods of assigning a covid pathological type and compositions for practicing the same, and methods of treating a subject for chronic covid-19
CN117304031A (zh) * 2023-09-05 2023-12-29 深圳大学 一种铁苋菜二萜类化合物、铁苋菜提取物及其在制备具有抗氧化和/或抗炎作用的产品中的应用
CN117414438B (zh) * 2023-11-01 2025-10-17 大连医科大学附属第一医院 一种靶向m1型巨噬细胞的多肽偶联药物及其应用
CN117919385B (zh) * 2024-02-05 2024-10-18 中国医学科学院医学实验动物研究所 IL-37在MERS-CoV感染疾病的治疗中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
US20030109486A1 (en) * 2001-10-31 2003-06-12 Eliezer Rapaport Methods and therapeutic compositions for utilization of adenosine 5'-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
EP2307042B1 (en) * 2008-06-25 2014-03-26 H. Lundbeck A/S Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
CN102223876A (zh) * 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
WO2012012498A2 (en) * 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
KR101374760B1 (ko) * 2011-10-26 2014-03-17 한국생명공학연구원 포볼 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
JP6977206B2 (ja) * 2016-03-31 2021-12-08 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
US12037389B2 (en) * 2017-12-01 2024-07-16 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same

Also Published As

Publication number Publication date
BR112022024226A2 (pt) 2023-01-31
US20260041660A1 (en) 2026-02-12
WO2021243007A2 (en) 2021-12-02
EP4304570A4 (en) 2025-01-22
US20230248684A1 (en) 2023-08-10
AU2021281257A1 (en) 2023-02-02
CN117015375A (zh) 2023-11-07
WO2021243007A3 (en) 2021-12-30
CA3180577A1 (en) 2021-12-02
JP2023528804A (ja) 2023-07-06
US20240082202A1 (en) 2024-03-14
EP4304570A2 (en) 2024-01-17
MX2022014958A (es) 2023-04-13
IL298593A (en) 2023-01-01
KR20230058014A (ko) 2023-05-02

Similar Documents

Publication Publication Date Title
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
PH12020551251A1 (en) Jak1 pathway inhibitors for the treatment of cytokine-related disorders
CO2020005417A2 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
MX389962B (es) Metodos para tratar trastornos mitocondriales y metabolicos.
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
CL2024000776A1 (es) Milvexian para la prevención y el tratamiento de trastornos tromboembólicos
BR112017025263A2 (pt) método para o tratamento de doença neurológica
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
MX2019010060A (es) Composiciones y metodo para tratar cancer.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
CL2023002812A1 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
MX2022010939A (es) Novedosos derivados sustituidos como inhibidores de la d-aminoacido oxidasa (daao).
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2021010445A (es) Metodos y aparatos para producir superficies rugosas.
MX377588B (es) Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.